非嚢胞性線維症気管支拡張症(NCFB)の市場インサイト・疫学・市場予測(~2028)

◆英語タイトル:Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Insight, Epidemiology and Market Forecast - 2028
◆商品コード:DATA00109006
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2019年12月
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD6,250 ⇒換算¥712,500見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD18,750 ⇒換算¥2,137,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Insight, Epidemiology and Market Forecast – 2028
DelveInsight’s “Non-Cystic Fibrosis Bronchiectasis (NCFB) – Market Insights, Epidemiology and Market Forecast – 2028” report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2017-2028

Non-Cystic Fibrosis Bronchiectasis (NCFB) Understanding and Treatment Algorithm
The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Non-Cystic Fibrosis Bronchiectasis (NCFB) in the US, Europe, and Japan are also provided in the report.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology
This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL’s views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Product Profiles & Analysis
This part of the Non-Cystic Fibrosis Bronchiectasis (NCFB) report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Outlook
The Non-Cystic Fibrosis Bronchiectasis (NCFB) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Share by Therapies
This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Report Insights
• Patient Population in Non-Cystic Fibrosis Bronchiectasis (NCFB)
• Therapeutic Approaches in Non-Cystic Fibrosis Bronchiectasis (NCFB)
• Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Analysis
• Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Size and Trends
• Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Opportunities
• Impact of upcoming Therapies in Non-Cystic Fibrosis Bronchiectasis (NCFB)

Non-Cystic Fibrosis Bronchiectasis (NCFB) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Non-Cystic Fibrosis Bronchiectasis (NCFB) Report Assessment
• Current Treatment Practices in Non-Cystic Fibrosis Bronchiectasis (NCFB)
• Unmet Needs in Non-Cystic Fibrosis Bronchiectasis (NCFB)
• Detailed Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Non-Cystic Fibrosis Bronchiectasis (NCFB) market
• Organize sales and marketing efforts by identifying the best opportunities for Non-Cystic Fibrosis Bronchiectasis (NCFB) market
• To understand the future market competition in the Non-Cystic Fibrosis Bronchiectasis (NCFB) market.

【レポートの目次】

1. Report Introduction
2. Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Overview at a Glance
2.1. Market Share Distribution of Non-Cystic Fibrosis Bronchiectasis (NCFB) in 2018
2.2. Market Share Distribution of Non-Cystic Fibrosis Bronchiectasis (NCFB) in 2028
3. Disease Background and Overview: Non-Cystic Fibrosis Bronchiectasis (NCFB)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Non-Cystic Fibrosis Bronchiectasis (NCFB) in 7MM
4.3. Total Prevalent Patient Population of Non-Cystic Fibrosis Bronchiectasis (NCFB) in 7MM – By Countries
5. Epidemiology of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.1.3. Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.1.4. Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.1.5. Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.1.6. Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.4.3. Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.4.4. Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.4.5. Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.4.6. Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.5.3. Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.5.4. Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.5.5. Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.5.6. Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.6.3. Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.6.4. Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.6.5. Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.6.6. Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.7.3. Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.7.4. Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.7.5. Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.7.6. Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.8.3. Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.8.4. Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.8.5. Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.8.6. Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.9.3. Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.9.4. Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.9.5. Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.9.6. Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Non-Cystic Fibrosis Bronchiectasis (NCFB)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Non-Cystic Fibrosis Bronchiectasis (NCFB) : 7MM Market Analysis
12.1. 7MM Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB)
12.2. 7MM Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB)
12.3. 7MM Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products
13. Non-Cystic Fibrosis Bronchiectasis (NCFB) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in United States
13.1.2. Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB) in United States
13.1.3. Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in Germany
13.2.1.2. Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB) in Germany
13.2.1.3. Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in France
13.2.2.2. Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB) in France
13.2.2.3. Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in Italy
13.2.3.2. Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB) in Italy
13.2.3.3. Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in Spain
13.2.4.2. Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB) in Spain
13.2.4.3. Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB) in United Kingdom
13.2.5.3. Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in Japan
13.3.2. Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB) in Japan
13.3.3. Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
*Indication Specific
Table 1: Total Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in 7MM
Table 2: Total Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in United States (2017-2028)
Table 4: Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in United States (2017-2028)
Table 5: Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in United States (2017-2028)
Table 6: Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in United States (2017-2028)
Table 7: Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in United States (2017-2028)
Table 8: Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Germany (2017-2028)
Table 9: Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Germany (2017-2028)
Table 10: Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Germany (2017-2028)
Table 11: Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Germany (2017-2028)
Table 12: Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Germany (2017-2028)
Table 13: Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in France (2017-2028)
Table 14: Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in France (2017-2028)
Table 15: Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in France (2017-2028)
Table 16: Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in France (2017-2028)
Table 17: Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in France (2017-2028)
Table 18: Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Italy (2017-2028)
Table 19: Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Italy (2017-2028)
Table 20: Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Italy (2017-2028)
Table 21: Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Italy (2017-2028)
Table 22: Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Italy (2017-2028)
Table 23: Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Spain (2017-2028)
Table 24: Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Spain (2017-2028)
Table 25: Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Spain (2017-2028)
Table 26: Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Spain (2017-2028)
Table 27: Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Spain (2017-2028)
Table 28: Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in UK (2017-2028)
Table 29: Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in UK (2017-2028)
Table 30: Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in UK (2017-2028)
Table 31: Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in UK (2017-2028)
Table 32: Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in UK (2017-2028)
Table 33: Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Japan (2017-2028)
Table 34: Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Japan (2017-2028)
Table 35: Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Japan (2017-2028)
Table 36: Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Japan (2017-2028)
Table 37: Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Japan (2017-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Table 42:7MM- Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Table 43:7MM- Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Table 44: United States-Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Table 45: United States-Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Table 46: United States-Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Table 47: Germany-Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Table 48: Germany-Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Table 49: Germany-Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Table 50: France-Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Table 51: France-Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Table 52: France-Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Table 53: Italy-Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Table 54: Italy-Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Table 55: Italy-Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Table 56: Spain-Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Table 57: Spain-Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Table 58: Spain-Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Table 59:UK-Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Table 60:UK-Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Table 61:UK-Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Table 62: Japan-Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Table 63: Japan-Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Table 64: Japan-Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 1: Total Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in United States (2017-2028)
Figure 4: Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in United States (2017-2028)
Figure 5: Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in United States (2017-2028)
Figure 6: Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in United States (2017-2028)
Figure 7: Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in United States (2017-2028)
Figure 8: Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Germany (2017-2028)
Figure 9: Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Germany (2017-2028)
Figure 10: Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Germany (2017-2028)
Figure 11: Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Germany (2017-2028)
Figure 12: Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Germany (2017-2028)
Figure 13: Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in France (2017-2028)
Figure 14: Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in France (2017-2028)
Figure 15: Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in France (2017-2028)
Figure 16: Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in France (2017-2028)
Figure 17: Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in France (2017-2028)
Figure 18: Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Italy (2017-2028)
Figure 19: Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Italy (2017-2028)
Figure 20: Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Italy (2017-2028)
Figure 21: Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Italy (2017-2028)
Figure 22: Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Italy (2017-2028)
Figure 23: Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Spain (2017-2028)
Figure 24: Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Spain (2017-2028)
Figure 25: Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Spain (2017-2028)
Figure 26: Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Spain (2017-2028)
Figure 27: Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Spain (2017-2028)
Figure 28: Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in UK (2017-2028)
Figure 29: Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in UK (2017-2028)
Figure 30: Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in UK (2017-2028)
Figure 31: Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in UK (2017-2028)
Figure 32: Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in UK (2017-2028)
Figure 33: Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Japan (2017-2028)
Figure 34: Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Japan (2017-2028)
Figure 35: Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Japan (2017-2028)
Figure 36: Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Japan (2017-2028)
Figure 37: Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) in Japan (2017-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Figure 42:7MM- Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 43:7MM- Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 44: United States-Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Figure 45: United States-Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 46: United States-Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 47: Germany-Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Figure 48: Germany-Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 49: Germany-Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 50: France-Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Figure 51: France-Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 52: France-Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 53: Italy-Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Figure 54: Italy-Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 55: Italy-Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 56: Spain-Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Figure 57: Spain-Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 58: Spain-Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 59:UK-Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Figure 60:UK-Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 61:UK-Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 62: Japan-Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in USD MM (2017-2028)
Figure 63: Japan-Market Share Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)
Figure 64: Japan-Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Therapies in USD MM (2017-2028)



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[非嚢胞性線維症気管支拡張症(NCFB)の市場インサイト・疫学・市場予測(~2028)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆